The 4Fr Nanopuncture POWERWAND is a power-injectable, peripheral IV catheter intended for use for both the administration of fluids/medications and withdrawing blood for diagnostic tests, according to the company. It is designed to deliver continuous IV therapy for a patient’s entire length of stay.
The device may be left in place for up to 29 days as per its FDA clearance.
“CDC Guidelines now say that patients whose IV therapy will likely exceed six days should have a midline or, if — and only if — indicated, a central line,” said Steve Bierman, MD, president and CEO of Access Scientific, in the release. “Based on recent studies, this means that nearly 30 percent of hospitalized patients should have a POWERWAND.”
Access Scientific is headquartered in San Diego.
Related Articles on FDA Clearances:
Iconacy Orthopedic Implants Receives FDA Clearance for Total Hip Replacement System
Covidien Receives FDA Clearance of Small Jaw Instrument for ENT Surgical Procedures
Precision Spine Receives FDA Clearance for Anterior Cervical Plate System
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.